Antibody persistence and immunologic memory in children vaccinated with 4 doses of pneumococcal conjugate vaccines: Results from 2 long-term follow-up studies

References

• Rudan I, O'Brien KL, Nair H, Liu L, Theodoratou E, Qazi S, Luksic I, Fischer Walker CL, Black RE, Campbell H, et al. Epidemiology and etiology of childhood pneumonia in 2010: estimates of incidence, severe morbidity, mortality, underlying risk factors and causative pathogens for 192 countries. J Glob Health 2013; 3:010401; PMID:23826505; http://dx.doi.org/10.7189/jogh.03.010101
   PubMed Web of Science ®Google Scholar
• Davis SM, Deloria-Knoll M, Kassa HT, O'Brien KL. Impact of pneumococcal conjugate vaccines on nasopharyngeal carriage and invasive disease among unvaccinated people: review of evidence on indirect effects. Vaccine 2013; 32:133-45; PMID:23684824; http://dx.doi.org/10.1016/j.vaccine.2013.05.005
   PubMed Web of Science ®Google Scholar
• Loo JD, Conklin L, Fleming-Dutra KE, Knoll MD, Park DE, Kirk J, Goldblatt D, O'Brien KL, Whitney CG. Systematic review of the indirect effect of pneumococcal conjugate vaccine dosing schedules on pneumococcal disease and colonization. Pediatr Infect Dis J 2014; 33 Suppl 2:S161-71; PMID:24336058; http://dx.doi.org/10.1097/INF.0000000000000084
   PubMed Web of Science ®Google Scholar
• Conklin L, Loo JD, Kirk J, Fleming-Dutra KE, Deloria Knoll M, Park DE, Goldblatt D, O'Brien KL, Whitney CG. Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on vaccine-type invasive pneumococcal disease among young children. Pediatr Infect Dis J 2014; 33 Suppl 2:S109-18; PMID:24336053; http://dx.doi.org/10.1097/INF.0000000000000078
   PubMed Web of Science ®Google Scholar
• De Wals P, Lefebvre B, Defay F, Deceuninck G, Boulianne N. Invasive pneumococcal diseases in birth cohorts vaccinated with PCV-7 and/or PHiD-CV in the province of Quebec, Canada. Vaccine 2012; 30:6416-20; PMID:22921290; http://dx.doi.org/10.1016/j.vaccine.2012.08.017
   PubMed Web of Science ®Google Scholar
• De Wals P, Lefebvre B, Markowski F, Deceuninck G, Defay F, Douville-Fradet M, Landry M. Impact of 2+1 pneumococcal conjugate vaccine program in the province of Quebec, Canada. Vaccine 2014; 32:1501-6; PMID:24486346; http://dx.doi.org/10.1016/j.vaccine.2013.11.028
   PubMed Web of Science ®Google Scholar
• Palmu AA, Jokinen J, Borys D, Nieminen H, Ruokokoski E, Siira L, Puumalainen T, Lommel P, Hezareh M, Moreira M, et al. Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial. Lancet 2013; 381:214-22; PMID:23158882; http://dx.doi.org/10.1016/S0140-6736(12)61854-6
   PubMed Web of Science ®Google Scholar
• Hausdorff WP, Hoet B, Adegbola RA. Predicting the impact of new pneumococcal conjugate vaccines: serotype composition is not enough. Expert Rev Vaccines 2015; 14:413-28; PMID:25266168; http://dx.doi.org/10.1586/14760584.2015.965160
   PubMed Web of Science ®Google Scholar
• Croxtall JD, Keating GM. Pneumococcal polysaccharide protein D-conjugate vaccine (Synflorix; PHiD-CV). Paediatr Drugs 2009; 11:349-57; PMID:19725600; http://dx.doi.org/10.2165/11202760-000000000-00000
   PubMedGoogle Scholar
• Jokinen J, Rinta-Kokko H, Siira L, Palmu AA, Virtanen MJ, Nohynek H, Virolainen-Julkunen A, Toropainen M, Nuorti JP. Impact of ten-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in Finnish children–a population-based study. PLoS One 2015; 10:e0120290; PMID:25781031; http://dx.doi.org/10.1371/journal.pone.0120290
   PubMed Web of Science ®Google Scholar
• Domingues CM, Verani JR, Montenegro Renoiner EI, de Cunto Brandileone MC, Flannery B, de Oliveira LH, Santos JB, de Moraes JC, for the Brazilian Pneumococcal Conjugate Vaccine Effectiveness Study Group. Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study. Lancet Respir Med 2014; 2:464-71; PMID:24726406; http://dx.doi.org/10.1016/S2213-2600(14)70060-8
   PubMed Web of Science ®Google Scholar
• Sgambatti S, Minamisava R, Bierrenbach AL, Toscano CM, Vieira MA, Policena G, Andrade AL. Early impact of 10-valent pneumococcal conjugate vaccine in childhood pneumonia hospitalizations using primary data from an active population-based surveillance. Vaccine 2016; 34:663-70; PMID:26706272; http://dx.doi.org/10.1016/j.vaccine.2015.12.007
   PubMed Web of Science ®Google Scholar
• Tregnaghi MW, Sáez-Llorens X, López P, Abate H, Smith E, Pósleman A, Calvo A, Wong D, Cortes-Barbosa C, Ceballos A, et al. Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: a double-blind randomized controlled trial. PLoS Med 2014; 11:e1001657; PMID:24892763; http://dx.doi.org/10.1371/journal.pmed.1001657
   PubMed Web of Science ®Google Scholar
• Afonso ET, Minamisava R, Bierrenbach AL, Escalante JJ, Alencar AP, Domingues CM, Morais-Neto OL, Toscano CM, Andrade AL. Effect of 10-valent pneumococcal vaccine on pneumonia among children, Brazil. Emerg Infect Dis 2013; 19:589-97; PMID:23628462; http://dx.doi.org/10.3201/eid1904.121198
   PubMed Web of Science ®Google Scholar
• Palmu AA, Jokinen J, Nieminen H, Rinta-Kokko H, Ruokokoski E, Puumalainen T, Borys D, Lommel P, Traskine M, Moreira M, et al. Effect of pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) on outpatient antimicrobial purchases: a double-blind, cluster randomised phase 3–4 trial. Lancet Infect Dis 2014; 14:205-12; PMID:24287186; http://dx.doi.org/10.1016/S1473-3099(13)70338-4
   PubMed Web of Science ®Google Scholar
• Vesikari T, Wysocki J, Chevallier B, Karvonen A, Czajka H, Arsène JP, Lommel P, Dieussaert I, Schuerman L. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatr Infect Dis J 2009; 28:S66-76; PMID:19325449; http://dx.doi.org/10.1097/INF.0b013e318199f8ef
   PubMed Web of Science ®Google Scholar
• Prymula R, Habib A, Francois N, Borys D, Schuerman L. Immunological memory and nasopharyngeal carriage in 4-year-old children previously primed and boosted with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) with or without concomitant prophylactic paracetamol. Vaccine 2013; 31:2080-8; PMID:23391599; http://dx.doi.org/10.1016/j.vaccine.2013.01.044
   PubMed Web of Science ®Google Scholar
• Silfverdal SA, Skerlikova H, Zanova M, Papúchová D, Traskine M, Borys D, Schuerman L. Anamnestic immune response in 3- to 4-year-old children previously immunized with 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine as 2-dose or 3-dose priming and a booster dose in the first year of life. Pediatr Infect Dis J 2011; 30:e155-63; PMID:21572373; http://dx.doi.org/10.1097/INF.0b013e31821feeb7
   PubMed Web of Science ®Google Scholar
• Chevallier B, Vesikari T, Brzostek J, Knuf M, Bermal N, Aristegui J, Borys D, Cleerbout J, Lommel P, Schuerman L. Safety and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with routine childhood vaccines. Pediatr Infect Dis J 2009; 28:S109-18; PMID:19325447; http://dx.doi.org/10.1097/INF.0b013e318199f62d
   PubMed Web of Science ®Google Scholar
• Dagan R, Poolman J, Siegrist CA. Glycoconjugate vaccines and immune interference: a review. Vaccine 2010; 28:5513-23; PMID:20600514; http://dx.doi.org/10.1016/j.vaccine.2010.06.026
   PubMed Web of Science ®Google Scholar
• Slack MH, Schapira D, Thwaites RJ, Burrage M, Southern J, Andrews N, Borrow R, Goldblatt D, Miller E. Immune response of premature infants to meningococcal serogroup C and combined diphtheria-tetanus toxoids-acellular pertussis-Haemophilus influenzae type b conjugate vaccines. J Infect Dis 2001; 184:1617-20; PMID:11740740; http://dx.doi.org/10.1086/324666
   PubMed Web of Science ®Google Scholar
• Wysocki J, Tejedor JC, Grunert D, Konior R, Garcia-Sicilia J, Knuf M, Bernard L, Dieussaert I, Schuerman L. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines. Pediatr Infect Dis J 2009; 28:S77-88; PMID:19325450; http://dx.doi.org/10.1097/INF.0b013e318199f609
   PubMed Web of Science ®Google Scholar
• Ekström N, Ahman H, Palmu A, Grönholm S, Kilpi T, Käyhty H, for The FinOM Study Group. Concentration and high avidity of pneumococcal antibodies persist at least 4 yearsears after immunization with pneumococcal conjugate vaccine in infancy. Clin Vaccine Immunol 2013; 20:1034-40; PMID:23658394; http://dx.doi.org/10.1128/CVI.00039-13
   PubMed Web of Science ®Google Scholar
• Madhi SA, Klugman KP, Kuwanda L, Cutland C, Käyhty H, Adrian P. Quantitative and qualitative anamnestic immune responses to pneumococcal conjugate vaccine in HIV-infected and HIV-uninfected children 5 yearsears after vaccination. J Infect Dis 2009; 199:1168-76; PMID:19265481; http://dx.doi.org/10.1086/597388
   PubMed Web of Science ®Google Scholar
• Madhi SA, Adrian P, Kuwanda L, Jassat W, Jones S, Little T, Soininen A, Cutland C, Klugman KP. Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine. Vaccine 2007; 25:2451-7; PMID:17023095; http://dx.doi.org/10.1016/j.vaccine.2006.09.019
   PubMed Web of Science ®Google Scholar
• Simell B, Auranen K, Kayhty H, Goldblatt D, Dagan R, O'Brien KL, for The Pneumococcal Carriage Group. The fundamental link between pneumococcal carriage and disease. Expert Rev Vaccines 2012; 11:841-55; PMID:22913260; http://dx.doi.org/10.1586/erv.12.53
   PubMed Web of Science ®Google Scholar
• Song JY, Moseley MA, Burton RL, Nahm MH. Pneumococcal vaccine and opsonic pneumococcal antibody. J Infect Chemother 2013; 19:412-25; PMID:23657429; http://dx.doi.org/10.1007/s10156-013-0601-1
   PubMed Web of Science ®Google Scholar
• Prymula R, Peeters P, Chrobok V, Kriz P, Novakova E, Kaliskova E, Kohl I, Lommel P, Poolman J, Prieels JP, et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet 2006; 367:740-8; PMID:16517274; http://dx.doi.org/10.1016/S0140-6736(06)68304-9
   PubMed Web of Science ®Google Scholar
• Knuf M, Szenborn L, Moro M, Petit C, Bermal N, Bernard L, Dieussaert I, Schuerman L. Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV). Pediatr Infect Dis J 2009; 28:S97-S108; PMID:19325452; http://dx.doi.org/10.1097/INF.0b013e318199f61b
   PubMed Web of Science ®Google Scholar
• Henckaerts I, Goldblatt D, Ashton L, Poolman J. Critical differences between pneumococcal polysaccharide enzyme-linked immunosorbent assays with and without 22F inhibition at low antibody concentrations in pediatric sera. Clin Vaccine Immunol 2006; 13:356-60; PMID:16522777; http://dx.doi.org/10.1128/CVI.13.3.356-360.2006
   PubMed Web of Science ®Google Scholar
• Poolman JT, Frasch CE, Käyhty H, Lestrate P, Madhi SA, Henckaerts I. Evaluation of pneumococcal polysaccharide immunoassays using a 22F adsorption step with serum samples from infants vaccinated with conjugate vaccines. Clin Vaccine Immunol 2010; 17:134-42; PMID:19889940; http://dx.doi.org/10.1128/CVI.00289-09
   PubMed Web of Science ®Google Scholar
• Henckaerts I, Durant N, De Grave D, Schuerman L, Poolman J. Validation of a routine opsonophagocytosis assay to predict invasive pneumococcal disease efficacy of conjugate vaccine in children. Vaccine 2007; 25:2518-27; PMID:17034907; http://dx.doi.org/10.1016/j.vaccine.2006.09.029
   PubMed Web of Science ®Google Scholar
• Brzostek J, Wysocki J, François N, Ravula S, Song Y, Dieussaert I, Schuerman L, Borys D. Immunogenicity and safety of 2-dose catch-up vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in the 6th year of life. Presented at: 32th Annual Meeting of the European Society for Paediatric Infectious Diseases; 2014 May 6–10; Dublin, Ireland
   Google Scholar